基本信息
浏览量:192
职业迁徙
个人简介
Professor Sir John Bell FRS HonFREng PMedSci, is Regius Professor of Medicine at Oxford University. His is a speaker at the School’s Silicon Valley Comes to Oxford event (SVCO13) which brings entrepreneurs from Silicon Valley to the School to engage with students, faculty and members of the wider Oxford entrepreneurial ecosystem.
Professor Bell went to Oxford as a Rhodes Scholar to train in medicine and undertook postgraduate training in London and at Stanford University. At Stanford he developed research interests in the area of immunology and genetics with a particular focus on characterising the molecular events associated with susceptibility to autoimmune diseases. He returned to Oxford as a Wellcome Trust Senior Clinical Fellow in 1987 and was elected to the Nuffield Professorship of Clinical Medicine in Oxford in 1992. In 2002, he became the Regius Professor of Medicine. He was appointed by the Chancellor of the Exchequer in 2006 to Chair the Office for the Strategic Coordination of Health Research (OSCHR), the body responsible to co-ordinate the research functions of the NIHR and the MRC. In 2008 he was made a Fellow of the Royal Society and was made a Knight Bachelor for his services to Medical Science. He has been President of The Academy of Medical Sciences since 2006.
Professor Bell has been extensively involved in the development of research programmes in genetics and genomics and in the development of a clinical research programme across the UK. He was the Founder of the Wellcome Trust Centre for Human Genetics and has led the significant expansion in biomedical research activities in the Clinical School in Oxford since 1992. His research programme has contributed to clearer understanding of genetic determinants of susceptibility in Type 1 diabetes and rheumatoid arthritis and also of the molecular interactions on the surface of the T-lymphocyte associated with immune activation. He has helped to pioneer a large number of high-throughput genomic methodologies applied to biomedical science, including programmes in structural genomics, ENU mutagenesis and genetics.
Professor Bell sits on a wide range of advisory panels for public and private sector bodies responsible for biomedical research in Canada, Sweden, Denmark, France, Singapore and the UK. He sat on the Scientific Advisory Board for AstraZeneca from 1997 to 2000 and has sat on the Scientific Advisory Board of the Roche Palo Alto facility since 1998. He is a non-executive director of Roche AG (since 2001) and of Genentech (since 2009). He is a member of the Bill and Melinda Gates Foundation Scientific Advisory Committee.
He is a founding director of three biotechnology start up companies. Professor Bell has been a member of Oxford University Council and MRC Council; he is a Board Member of the UK Clinical Research Collaboration and UK Biobank and is Chairman of the Oxford Health Alliance, a private public partnership that sponsors research and advocacy on chronic disease globally.
研究兴趣
论文共 301 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Adriano de Bernardi Schneider, Michelle Su,Angie S. Hinrichs,Jade Wang,Helly Amin,John Bell,Debra A. Wadford,Aine O'Toole,Emily Scher, Marc D. Perry,Yatish Turakhia,Nicola De Maio,
David M Berman,John I Bell
medRxiv (Cold Spring Harbor Laboratory) (2023)
Debra A. Wadford, Nikki Baumrind, Elizabeth F. Baylis,John M. Bell, Ellen L. Bouchard,Megan Crumpler, Eric M. Foote, Sabrina Gilliam,Carol A. Glaser,Jill K. Hacker, Katya Ledin,Sharon L. Messenger,
Frontiers in Public Health (2023): 1249614
引用0浏览0WOS引用
0
0
medRxiv (Cold Spring Harbor Laboratory) (2022)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn